Overview

Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy

Status:
RECRUITING
Trial end date:
2027-05-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine (SUZ) in participants with pain associated with diabetic peripheral neuropathy (DPN).
Phase:
PHASE3
Details
Lead Sponsor:
Vertex Pharmaceuticals Incorporated
Treatments:
Pregabalin